59^thEASD Annual Meeting of the European Association for the Study of Diabetes

Hamburg, Germany, 2 – 6 October 2023

Diabetologia volume 66, pages 1–536 (2023)

Sections

• OP 01 Tirzepatide: all things must SURPASS
• OP 02 Present, future and future future of insulin therapy
• OP 03 Pregnancy and diabetes: lessons from cohort studies
• OP 04 Diet and exposome
• OP 05 Walking towards better treatments for diabetic feet and neuropathy
• OP 06 Adipocytes and adipose tissue plasticity
• OP 07 Regulation of islet function through gene editing and modification
• OP 08 Towards curing obesity
• OP 09 Treatment beyond metformin
• OP 10 Activating two or three G´s; one of us is lonely
• OP 11 Be(a)ware of hypoglycaemia unawareness
• OP 12 Diabetes and the brain
• OP 13 Concerning insulin resistance
• OP 14 Regulation of islet hormone secretion in type 1 diabetes and type 2 diabetes
• OP 15 Incretins and glucagon in action
• OP 16 What new in type 1 diabetes treatment: focus on the islet cells
• OP 17 New approaches: a magical mystery tour
• OP 18 Highlights in type 1 diabetes
• OP 19 Why does diabetes make one sad?
• OP 20 NAFLD and omics
• OP 21 New strategies for diabetic retinopathy from mice to the clinic
• OP 22 Improving the diagnosis and prediction of kidney disease progression
• OP 23 More news from SGLT2s
• OP 24 All around pregnancy
• OP 25 Muscles at work
• OP 26 Many digits in digital diabetes
• OP 27 Adipocyte impact on obesity and metabolic health
• OP 28 Novel signalling pathways regulating islet function
• OP 29 Cardiac complications in type 1 and type 2 diabetes
• OP 30 Years and years
• OP 31 Future for type 1 diabetes treatment
• OP 32 Obesity, liver and beyond
• OP 33 Are we what we eat?
• OP 34 Diabetic neuropathy from the brain to the bowels
• OP 35 Omics and more: unbiased approaches to tackle obesity
• OP 36 Cardiovascular risk, complications and fitness
• OP 37 Inflammation: foe or friend?
• OP 38 How dreaming about artificial pancreas enters the real world (data)
• OP 39 Pregnancy, diabetes and metabolic health (of mother and child)
• OP 40 What is new in 2023 for the treatment of diabetic kidney disease?
• OP 41 SNPs, risk scores and gene therapy
• OP 42 Risk factors and biomarkers of CVD
• OP 43 Old dogs, new tricks
• OP 44 Checking in on beta cell function
• OP 45 Thinking outside the box to protect the kidney and the foot
• OP 46 Endothelium and diabetes complications
• OP 47 Senescence and age
• OP 48 Different approaches to map signal pathways in islet cells
• OP 49 Caring for care delivery
• OP 50 Fatty liver, faulty liver
• OP 51 ”With a little help from my friends”: therapies and combinations
• OP 52 Looking to the future: risks and benefits of glycaemic control in diabetic retinopathy
• OP 53 Elevating and (making) exciting diabetes education
• OP 54 Risk factors for complications and mortality
• OP 55 How the beta cells die and can be rescued
• OP 56 The brain in control
• SO 01 Weight across the lifespan
• SO 02 Lifestyle matters
• SO 03 From single nutrients to dietary patterns
• SO 04 Viruses and infections
• SO 05 Autoimmunity in diabetes
• SO 06 Diagnosis and prediction
• SO 07 Mechanistic insights
• SO 08 Coming from the heart
• SO 09 Novel risk factors and treatments
• SO 10 Body and brain
• SO 11 Obesity and prediabetes
• SO 12 Epigenetics
• SO 13 Monogenic diabetes
• SO 14 Heterogeneity of diabetes
• SO 15 Transcriptional regulation in islet cells
• SO 16 Different approaches to study hormone secretion regulation
• SO 17 Modulators of beta cell signal transduction: How do they work?
• SO 18 Role of immune cells in type 1 diabetes and type 2 diabetes
• SO 19 Transplantation of islet and stem cells today and tomorrow
• SO 20 Roads leading to apoptosis in beta cells
• SO 21 Protection of beta cells
• SO 22 Inflammation in type 1 diabetes
• SO 23 Drug interventions in diabetes and associated disease
• SO 24 Grades of insulin sensitivity
• SO 25 Exercise as medicine
• SO 26 Hormones from the gut and the liver
• SO 27 Glucagon secretion and peripheral hormone action
• SO 28 Pregnant with type 1 diabetes and adverse pregnancy outcomes
• SO 29 Gestational diabetes
• SO 30 Insulin secretion: for better or for worse
• SO 31 It’s in the brain
• SO 32 Keeping focus on GLP1
• SO 33 Weight loss rules
• SO 34 Metabolic flames
• SO 35 Sex and time matters
• SO 36 Obesity and diabetes across generations
• SO 37 Hormonal control of obesity
• SO 38 Fantastic fats and where to find them
• SO 39 Fat across organs
• SO 40 Metabolism in humans
• SO 41 Novel players in adipocyte biology
• SO 42 Tirzepatide: SURPASSing the vibe check
• SO 43 Small molecules to combat a large disease
• SO 44 I heard the news today: novel incretins
• SO 45 Dual agonism: two of us
• SO 46 GLP-1 receptor agonists: action beyond glycaemia
• SO 47 Incretin trials: trying new directions
• SO 48 Incretins: a day in the life
• SO 49 Therapies: here, there and everywhere
• SO 50 Type 1 diabetes
• SO 51 SGLT2 inhibitors: trying new directions
• SO 52 Targeting muscle, kidney and liver
• SO 53 Miscellaneous: The White Album
• SO 54 Carbohydrates: time matters
• SO 55 Nutrition: strawberry fields or glass onions?
• SO 56 Devising diabetes devices
• SO 57 How to make a good script for insulin therapy for the demanding audience
• SO 58 To hell with the hypo
• SO 59 How does AID aid the patients?
• SO 60 How bright is the hybrid?
• SO 61 Refining and redefining insulin therapy in type 1 diabetes
• SO 62 If it is Tuesday, it is time for insulin injection
• SO 63 Patient-centered perfecting of insulin therapy
• SO 64 Quantifying hypoglycaemia: from mild to mad
• SO 65 Yin and yang of CGMing
• SO 66 Insulin therapy can be better and cheaper
• SO 67 Un/successful fitting diabetes in a health care system
• SO 68 Where do the happiest people with diabetes live?
• SO 69 ”When I’m sixty-four” (low and not-so-young)
• SO 70 Will rise of the machines terminate diabetes?
• SO 71 Making it all work
• SO 72 When diabetes goes digital
• SO 73 More or less likely but still important determinants of diabetes care
• SO 74 Clinical observations to improve the prediction and progression of diabetic kidney disease
• SO 75 Clinical outcomes and biomarkers in diabetic kidney disease
• SO 76 Diabetic kidney disease pathophysiology from cells to mice, and humans
• SO 77 New insights to the drivers of diabetic retinopathy progression
• SO 78 Biomarkers and risk factors for diabetic foot disease and peripheral neuropathy
• SO 79 Diabetic complications: observational studies from nerves to blood vessels
• SO 80 Beyond the clinical examination: emerging diagnostics in diabetic neuropathy
• SO 81 Diabetes and the heart
• SO 82 Trends in cardiovascular complications
• SO 83 Predicting cardiovascular events in diabetes
• SO 84 Macrovascular disease: basic science
• SO 85 Diabetes, lipids and the vessels
• SO 86 Diabetic complications from head to toe
• SO 87 Diabetic complications: the heart, the kidney and the bone
• SO 88 Pathogenic mechanism of diabetic complications
• SO 89 Diabetes: a systemic disease
• SO 90 Epidemiology of cardiovascular disease in diabetes: What is new?
• SO 91 Experimental models of diabetes: related complications
• SO 92 Cognitive impairment in diabetes
• SO 93 The Liver: from cell to clinic
• SO 94 Diabetes and NAFLD
• SO 95 NAFLD: relevant biomarkers
• SO 96 NAFLD: future treatment
• Additional information
• Rights and permissions
• About this article